The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that the Company's actual future results or performance may be materially different from what the Company expects. In this announcement, statements of, or references to, the intentions of the Company and/or any of its directors are made as of the date of this announcement. Any of these intentions may alter in light of future development.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

VOLUNTARY ANNOUNCEMENT

MEETING OF PRIMARY ENDPOINT IN PHASE III CLINICAL TRIAL OF TAB008

This announcement is made by TOT BIOPHARM International Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the predefined primary endpoint in relation to the randomized Phase III clinical trial of TAB008 has recently been met. Such primary endpoint compares the efficacy of TAB008 and Avastin by measuring the objective response rates (ORR) of two groups of patients within the first 18 weeks of treatment (i.e. six three-week cycles). The Group will continue to push forward the new drug application (NDA) of TAB008 as scheduled.

TAB008 is an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb) drug candidate and is a biosimilar drug candidate to bevacizumab, which is sold under the trade name of Avastin. Avastin has been the most widely used anti-VEGF mAb drug with abundant real-world evidence of its efficacy and safety since its entry into the market in 2004. The Group intends to use "Pusintin (朴欣汀)" as the trade name for TAB008. TAB008 is currently the Group's most advanced biological drug candidate and is the Company's core product.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, TAB008 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

By order of the Board
TOT BIOPHARM International Company Limited
Yeh-Huang, Chun-Ying
Executive Director

Hong Kong, 21 April 2020

As at the date of this announcement, the executive directors of the Company are Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.